Statins and neuroprotection: A prescription to move the field forward

W. Gibson Wood, Gunter P. Eckert, Urule Igbavboa, Walter E. Müller

Research output: Chapter in Book/Report/Conference proceedingConference contribution

127 Scopus citations


There is growing interest in the use of statins, HMG-CoA reductase inhibitors, for treating specific neurodegenerative diseases (e.g., cerebrovascular disease, Parkinson's disease, Alzheimer's disease, multiple sclerosis) and possibly traumatic brain injury. Neither is there a consensus on the efficacy of statins in treating the aforementioned diseases nor are the mechanisms of the purported statin-induced neuroprotection well-understood. Part of the support for statin-induced neuroprotection comes from studies using animal models and cell culture. Important information has resulted from that work but there continues to be a lack of progress on basic issues pertaining to statins and brain that impedes advancement in understanding how statins alter brain function. For example, there are scant data on the pharmacokinetics of lipophilic and hydrophilic statins in brain, statin-induced neuroprotection versus cell death, and statins and brain isoprenoids. The purpose of this mini-review will be to examine those aforementioned issues and to identify directions of future research.

Original languageEnglish (US)
Title of host publicationNeuroprotective Agents
Subtitle of host publicationNinth International Conference
PublisherBlackwell Publishing Inc
Number of pages8
ISBN (Print)9781573317771
StatePublished - Jun 2010

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Alzheimer's disease
  • Cerebrovascular disease
  • Cholesterol
  • HMG-CoA reductase
  • Isoprenoids
  • Neurodegeneration
  • Nneuroprotection
  • Statins
  • Stroke


Dive into the research topics of 'Statins and neuroprotection: A prescription to move the field forward'. Together they form a unique fingerprint.

Cite this